Abstract Number: 2378 • ACR Convergence 2023
Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort
Background/Purpose: ANCA-associated vasculitis (AAV) commonly causes renal damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Quantitative descriptions of…Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…Abstract Number: 597 • 2018 ACR/ARHP Annual Meeting
Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry
Background/Purpose: Biologics in combination with methotrexate (MTX) are being incorporated earlier in rheumatoid arthritis (RA) therapy to prevent long-term damage and maintain patient function. While…Abstract Number: 1932 • 2012 ACR/ARHP Annual Meeting
Clinical Features of an Aromatase Inhibitor Associated Syndrome Presenting As Rheumatoid Arthritis Ronald J. Anderson, MD, Brigham &Women’s Hospital
Background/Purpose: The aromatase inhibitors (AI); anastrozole, letrozole and exemestane are used in the treatment of postmenopausal women with estrogen receptor positive breast cancer. Arthralgias occur…Abstract Number: 0034 • ACR Convergence 2023
Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank
Background/Purpose: Antinuclear antibodies (ANA) to intranuclear particles are found in the blood of people with and without autoimmune diseases. To our knowledge, only 1 past…Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…Abstract Number: 1003 • ACR Convergence 2023
A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis
Background/Purpose: Rheumatic disorders frequently affect women of childbearing age. These diseases and medications used to treat them can have adverse effects on fertility and fetuses.…Abstract Number: 1023 • ACR Convergence 2023
Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes
Background/Purpose: IgG4-related disease (IgG4-RD) is a multi-organ fibroinflammatory disease with an autoimmune basis that can affect essentially any organ. Differences in phenotypic expression between males…Abstract Number: 1116 • ACR Convergence 2023
The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System
Background/Purpose: A substantial proportion of gout patients have type 2 diabetes (T2DM), heart failure (HF), and chronic kidney disease (CKD), for which SGLT2i treatment is…Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…Abstract Number: 1542 • ACR Convergence 2023
The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…Abstract Number: 2377 • ACR Convergence 2023
The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis
Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »